Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (207)	12/11/2000 6:55:14 PM
From: tom pope	Read Replies (1) \| Respond to of 1784

Since BTRN's stem cell interests are in Australia, they might benefit from a Bush presidency, it seems to me.

To: tuck who wrote (207)	12/11/2000 11:02:54 PM
From: PuddleGlum	Read Replies (1) \| Respond to of 1784

You might add GCOR to your list. They're trying to become a gene discovery and functional genomics platform provider (isn't everybody?) but they currently have sales of enzymes, so I'd consider that "trickle". Regarding AGNT, I have yet to delve into that one to figure out what the difference is between parallel chemistry and combinatorial chemistry. If there's no difference then we have another DVSA/SMMX/MAXY type of company. But AGNT sells instruments, which the others don't, to my knowledge. Great timing on BDAL!